Overview
MBRX market data
Price History
MBRX price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for MBRX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Moleculin CEO Highlights Preliminary Unblinded Efficacy Results From First 45 Patients Enrolled In Part A Of Pivotal Phase 2/3 MIRACLE Trial Evaluating Annamycin In R/R AML During Investor SegmentBenzinga · Jul 6, 2026, 12:50 PM
Why is Moleculin Stock Falling Today?Benzinga · Jun 30, 2026, 6:05 PM
Moleculin Biotech Announces Its Data From Phase 2/3 MIRACLE Study For Both Annamycin Treatment Arms Shows Efficacy; Composite Complete Remission Reaches 50%, 57% In Respective ArmsBenzinga · Jun 30, 2026, 12:40 PM
8-K filing — Moleculin Biotech, Inc. (MBRX)SEC EDGAR · Jun 30, 2026, 12:30 PM
Moleculin Biotech Enrolls 45th Participant In Its Pivotal Phase 2B/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Relapsed Or Refractory Acute Myeloid LeukemiaBenzinga · Jun 4, 2026, 12:55 PM
Moleculin Biotech Announces That New Data Further Reinforcing The Differentiated Cardiac Safety Profile Of Its Lead Drug Candidate, Annamycin, Were Presented At The American Society Of Clinical Oncology Annual MeetingBenzinga · May 29, 2026, 12:26 PM
Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) EstimateBenzinga · May 15, 2026, 1:25 PM
Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data UnblindingBenzinga · May 13, 2026, 4:41 PM
Moleculin Announces Data From Phase 2B/3 "MIRACLE" Trial Evaluating Annamycin In Combination With CytarabineBenzinga · May 13, 2026, 12:06 PM